

## Literatur zum Artikel „Vitamin D3 und K2 bei Osteoporose und Brustkrebs“, März 2016

- [1] Gröber U, Spitz J, Holick MF, Wacker M, Kisters K (2013): Vitamin D: Update 2013: Von der Rachitis-Prophylaxe zur allgemeinen Gesundheitsvorsorge. Deutsche Apotheker Zeitung; 153(15): 1518-1526.
- [2] Kanellakis S, Moschonis G, Tenta R, Schaafsma A, van den Heuvel EG, Papaioannou N, Lyritis G, Manios Y (2012): Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. *Calcif Tissue Int*; 90(4): 251-262.
- [3] Michalek JE, Preuss HG, Croft HA, Keith PL, Keith SC, Dapilmoto M, Perricone NV, Leckie RB, Kaats GR (2011): Changes in total body bone mineral density following a common bone health plan with two versions of a unique bone health supplement: a comparative effectiveness research study. *Nutr J*; 10: 32.
- [4] Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E (2013): Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. *Osteoporos Int*; 24: 2499-2507.
- [5] Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006): Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med*; 166: 1256-1261.
- [6] Cui Y, Rohan TE (2006): Vitamin D, calcium, and breast cancer risk: a review. *Cancer Epidemiol Biomarkers Prev*; 15(8): 1427-1437.
- [7] Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL (2013): Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. *Medicine (Baltimore)*; 92(3): 123-131.
- [8] Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N (2009): Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. *J Clin Oncol*; 27(23): 3757-3763.
- [9] Maier GS, Horas K, Kurth AA, Lazovic D, Seeger JB, Maus U (2015): Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma. *Anticancer Res*; 35(11): 6281-6285.
- [10] Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008): Response of serum carboxylated and undercarboxylated Osteocalcin to alendronate monotherapy and combined therapy with vitamin K<sub>2</sub> in postmenopausal women. *J Bone Miner Metab*; 26: 260-264.
- [11] Mangin M, Sinha R, Fincher K (2014): Inflammation and vitamin D: the infection connection. *Inflamm Res*; 63(10): 803-819.
- [12] Gröber U, Kisters K, Spitz J, Adamietz IA (2015): Vitamin D in der onkologischen Intervention: Update 2015. *DZO*; 47(4): 173-177.
- [13] Gröber U, Reichrath J, Holick MF, Kisters K (2015): Vitamin K: an old vitamin in a new perspective. *Dermatoendocrinol*; 6(1): e968490.
- [14] Booth SL (2012): Vitamin K: food composition and dietary intakes. *Food Nutr Res*; 56.
- [15] Schurgers LJ, Teunissen KJ, Hamulyák K, Knapen MH, Vik H, Vermeer C (2007): Vitamin K-containing dietary supplements: comparison of synthetic vitamin K<sub>1</sub> and natto-derived menaquinone-7. *Blood*; 109(8): 3279-3283.
- [16] Theuwissen E, Magdeleyne S, Braam LA (2014): Vitamin K-status in healthy volunteers. *Food Funct*; 5: 229-234.